Post-Approval Safety Risks Threaten Mesoblast’s Ryoncil Commercialization in Fragile Pediatric SR-aGVHD MarketTip Ranks·6 hours agoMESO-4.07%
3 Penny Stocks With Stronger Balance Sheets Worth A Closer LookSimplywall·Aug 24 at 08:24 PMMESO-4.07%
Mesoblast to host webcast on full-year financial results and corporate updatePUBT·Aug 24 at 06:03 AMMESO-4.07%
Mesoblast Stock Leads 3 Australian Growth Shares With Strong Earnings ExpectationsSimplywall·Aug 22 at 02:42 PMLYSDY-3.57%MESO-4.07%
Mesoblast Targets $10 Billion Market With Regenerative Back Pain Treatmentbenzinga_article·Aug 17 at 12:45 PMMESO-4.07%
H World Group Posts Upbeat Q2 Results, Joins Almonty Industries, Diana Shipping And Other Big Stocks Moving Higher On Mondaybenzinga_article·Aug 17 at 08:51 AMMESO-4.07%SMTC-7.91%
Mesoblast Achieves Major Milestone Completing Patient Treatment in Pivotal Phase 3 Trial for Chronic Low Back PainUnusual Whales·Aug 16 at 07:37 PMMESO-4.07%
Mesoblast completes dosing in Phase 3 rexlemestrocel-L trial for chronic low back painPUBT·Aug 16 at 07:35 PMMESO-4.07%
Swarmer Posts Downbeat Q2 Results, Joins TSS, ARS Pharmaceuticals, Globant And Other Big Stocks Moving Lower In Friday’s Pre-Market Sessionbenzinga_article·Aug 14 at 07:06 AMMESO-4.07%GLOB+0.87%
Stop Falling for Earnings Spin: The True Survivor Game of Biotech, AI Edges, and India ETFsGlobal Report·Aug 11 at 04:43 AMMESO-4.07%TVTX-2.74%
Mesoblast (NASDAQ:MESO) Shares Gap Up - What's Next?Market Beat·Aug 10 at 12:00 PMMESO-4.07%JPM+0.96%
